Plinest Polynucleotide HPT® Wins ‘Best Injectable for Mature Skin’ at the 2026 Menopause in Practice Awards

Plinest Polynucleotide HPT® has been named Best Injectable for Mature Skin at the 2026 Menopause in Practice Awards. The award was presented to DermaFocus at the ceremony held at the Grand Connaught Rooms in London on 6 February 2026.

The Menopause in Practice Awards recognise work in menopause care across aesthetics, dermatology, gynaecology and holistic health. The awards aim to highlight clinical standards, safety and treatment approaches supporting patients during perimenopause and menopause.

Plinest Polynucleotide HPT® (Highly Purification Technology) is indicated for skin quality improvement and is used in regenerative aesthetic treatments. The product is designed to support skin affected by biological changes associated with perimenopause and menopause, including reduced collagen production, changes in elasticity and skin thinning.

The 2026 awards ceremony followed a Great Gatsby theme and brought together professionals from across the aesthetics and menopause care sectors.

DermaFocus Co-Founder, Milad Bemana, comments:

“We are delighted that Plinest Polynucleotide HPT®️ has been awarded winner in this years Menopause in Practice Awards. To be recognised by our peers for the work that we do really shines a light on our commitment to excellence in the industry as well as to our partners and their patients. We introduced regenerative aesthetics to the UK long before it was the buzzword it is today, finding gaps, backed with evidence, to offer future-focused skin solutions. With the menopause conversation continuing to dominate both media and clinic demand, this award positions Plinest Polynucleotide HPT®️ as a gold-standard injectable, suited to the biological reality of skin for women going through menopause, not just aesthetic trends.”